Page 35 - anuario 2024

myocardial infarction in 52 countries (the INTERHEART study): case-control
study. Lancet. 2004 Sep 11-17;364(9438):937-52.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart
disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov
19;344(8934):1383-9.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The
effect of pravastatin on coronary events after myocardial infarction in patients
with average cholesterol levels. Cholesterol and Recurrent Events Trial
investigators. N Engl J Med. 1996 Oct 3;335(14):1001-9.
5. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al;
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in
Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering
with statins after acute coronary syndromes. N Engl J Med. 2004 Apr
8;350(15):1495-504.
6. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al;
Treating to New Targets (TNT) Investigators. Intensive lipid lowering with
atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 Apr
7;352(14):1425-35.
7. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR,
et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular
events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014 Aug 5;64(5):485-
94.
8. Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden
K, et al. Association Between Baseline LDL-C Level and Total and
Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-
analysis. JAMA. 2018 Apr 17;319(15):1566-1579.
9. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al;
ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J.
2021 Sep 7;42(34):3227-3337.

35